Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period

Pharmacological Reports

Volumn 65, Issue 1, 2013, Pages 30-43

  Ratajczak, Piotr ^a   Kus, Krzysztof ^a   Jarmuszkiewicz, Zofia ^a   Woźniak, Anna ^a   Cichocki, Michał ^a   Nowakowska, Elzbieta ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Aripiprazole; Cognitive functions; Depression; Olanzapine; Prenatally stressed animals

Indexed keywords

APOMORPHINE; ARIPIPRAZOLE; CORTICOSTERONE; OLANZAPINE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; CHRONIC STRESS; COGNITION; COGNITIVE DEFECT; COLD EXPOSURE; CONTROLLED STUDY; DEPRESSION; FEMALE; FORCED SWIMMING TEST; IMMOBILIZATION; LATENT PERIOD; LOCOMOTION; MAZE TEST; NONHUMAN; PERINATAL PERIOD; PRENATAL STRESS; RAT; SCHIZOPHRENIA; SINGLE DRUG DOSE; SOCIAL STRESS; SPATIAL MEMORY;

EID: 84875782002     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)70961-7     Document Type: Article

References (88)

1. Addington J, Addington D: Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr Res, 2000, 44, 47-56.
2. Andreasen N, Carpenter W, Kane JM, Lasser RA, Marder SR, Weinberger DR: Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry, 2005, 162, 441-449.
3. Bayer SA, Altman J, Russo RJ, Zhang X: Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology, 1993, 14, 83-144.
4. Bilder RM, Bogerts B, Ashtari M, Wu H, Alvir JM, Jody D, Reiter G et al.: Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophr Res, 1995, 17, 47-58.
5. Braff DL, Geyer MA: Sensorimotor gating and schizophrenia: Human and animal model studies. Arch Gen Psychiatry, 1990, 47, 181-188.
6. Braga PQ, Dias FR, Carey RJ, Carrera MP: Low dose apomorphine induces context-specific sensitization of hypolocomotion without conditioning: support for a new state dependent retrieval hypothesis of drug conditioning and sensitization. Pharmacol Biochem Behav, 2009, 93, 128-133.
7. Burda K, Czubak A, Kus K, Nowakowska E, Ratajczak P, Zin J: Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep, 2011, 63, 898-907.
8. Conroy SK, Rodd Z, Chambers RA: Ethanol sensitization in neuro developmental lesion model of schizophrenia rats. Pharmacol Biochem Behav, 2007, 86, 386-394.
9. Cook CCH, Palsson G: A genetic linkage study of the D2 dopamine receptor locus in heavy drinking and alcoholism. Br J Psychiatry, 1996, 169, 243-248.
10. Costa e Silva JA, Alvarez N, Mazzotti G, Gattaz WF, Ospina J, Larach V, Starkstein S et al.: Olanzapine as alternative therapy for patients with haloperidol-induced extra pyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J Clin Psycho pharmacol, 2001, 21, 375-81.
11. Dewan MJ, Pandurangi AK, Levy BF, Boucher ML, Major LF: Are schizophrenics with abnormal dexamethasone suppression test results a distinct subgroup? Acta Psychiatr Scand, 1985, 72, 274 -277.
12. Dias R, Robbins TW, Roberts AC: Dissociation in prefrontal cortex of affective and attentional shifts. Nature, 1996, 380, 69-72.
13. Díaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F: Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci, 2005, 25, 10831-10843.
14. Duncan GE, Zorn S, Lieberman JA: Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypo function hypotheses of schizophrenia. Mol Psychiatry, 1999, 4, 418-428.
15. Elman I, Adler CM, Malhotra AK, Bir C, Pickar D, Breier A: Effect of acute metabolic stress on pituitaryadrenal axis activation in patients with schizophrenia. Am J Psychiatry, 1998, 155, 979-981.
16. Featherstone RE, Burton CL, Coppa-Hopman R, Rizos Z, Sinyard J, Kapur S, Fletcher PJ: Gestational treatment with methylazoxy methanol (MAM) that disrupts hippocampal-dependent memory does not alter behavioural response to cocaine. Pharmacol Biochem Behav, 2009, 93, 383-390.
17. Flaum M, O'Leary DS, Swayze VW, Miller DD, Arndt S, Andreasen NC: Symptom dimensions and brain morphology in schizophrenia and related psychotic disorders. J Psychiatry Res, 1995, 29, 261-276.
18. Fone KCF, Porkess MV: Behavioural and neurochemical effects of post-weaning social isolation in rodents - relevance to developmental neuropsychiatric disorder. Neurosci Biobehav Rev, 2008, 32, 1087-1102.
19. Francis DD, Caldji C, Champagne F: The role of corticotropin-releasing factor norepinephrine systems in mediating the effects of early experience on the development of behavioral and endocrine responses to stress. Biol Psychiatry, 1999, 46, 1153-1166.
20. Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR: A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry, 2008, 69, 302-309.
21. Goldman-Rakic PS: Cellular basis of working memory. Neuron 1995, 14, 477-485.
22. Gulley JM, Kuwajima M, Mayhill E, Rebec GV: Behavior-related changes in the activity of substantia nigra pars reticulata neurons in freely moving rats. Brain Res, 1999, 845, 68-76.
23. Hauser J: Genes-environment interaction in schizophrenia. Psychiatria, 2007, 4, 153-159.
24. Hayashi A, Nagaoka M, Yamada K, Miake Y, Okado N: Maternal stress induces synaptic loss and developmental disabilities in offspring of maternal stress. Int J Dev Neurosci, 1998, 16, 209-216.
25. Hibberd C, Yau J, Seckl JR: Glucocorticoids and the ageing hippocampus. J Anat, 2000, 197, 553-562.
26. Hintze B, Wciórka J, Borkowska A: Working memory and executive functions disorders in schizophrenic patients in partial remission of psychopathological symptoms. Psychiatria, 2007, 4, 45-52.
27. Joca SR, Skalisz LL, Beijamini V, Vital MA, Andreatini R: The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission. Eur Neuropsychopharmacol, 2000, 10, 223-328.
28. Kapur S, Seeman P: NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors - implications for models of schizophrenia. Mol Psychiatry, 2002, 7, 837-44.
29. Kinney DK, Munir KM, Crowley DJ, Miller AM: Prenatal stress and risk for autism. Neurosci Biobehav Rev, 2008, 32, 1519-1532.
30. Kinnunen AK, Koenig JI, Bilbe G: Repeated variable prenatal stress alters pre- and postsynaptic gene expression in the rat frontal pole. J Neurochem, 2003, 86, 736-748.
31. Kleven MS, Barret-Grevoz C, Slot LB, Newman-Tancredi A: Novel antipsychotic agents with 5-HT1A agonist properties: role of 5-HT1A receptor activation in attenuation of catalepsy in rats. Neuropharmacology, 2005, 49, 135-143.
32. Koenig JI, Elmer GI, Shepard P, Lee PR, Mayo C, Joy B, Herscher E et al.: Stress during gestation produces alterations in adult rat behavior: relevance to schizophrenia. Soc Neurosci Abstr, 2002, 495.6.
33. Koenig JI, Elmer GI, Shepard PD, Lee PR, Mayo CH, Joy B, Hercher E, Brady D: Prenatal exposure to a repeated variable stress paradigm elicits behavioral and neuroendocrinological changes in the adult offspring: potential relevance to schizophrenia. Behav Brain Res, 2005, 156, 251-261.
34. Koenig JI, Kirkpatrick B, Lee P: Glucocorticoid hormones and early brain development in schizophrenia. Neuropsychopharmacology, 2002, 27, 309-318.
35. Lammers CH, Garcia-Borreguero D, Schmider J, Gotthardt U, Dettling M, Holsboer F, Heuser IJ: Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol Psychiatry, 1995, 38, 803- 807.
36. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E et al.: Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA, 1996, 93, 9235-40.
37. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J: Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry, 2004, 161, 2 Suppl, 1-56.
38. Lemaire V, Koehl M, Le Moal M, Abrous DN: Prenatal stress produces learning deficits associated with an inhibition of neurogenesis in the hippocampus. Proc Natl Acad Sci USA, 2000, 97, 11032-11037.
39. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 2009, 373, 31-41.
40. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C et al.: A metaanalysis of head-to-head comparisons of secondgeneration antipsychotics in the treatment of schizophrenia. Am J Psychiatry, 2009, 166, 152-63.
41. Lipska BK, Weinberger DR: To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology, 2000, 23, 223-239.
42. Llorente R, Arranz L, Marco EM, Moreno E, Puerto M, Guaza C, De la Fuente M, Viveros MP: Early maternal deprivation and neonatal single administration with a cannabinoid agonist induce long-term sex-dependent psychoimmunoendocrine effects in adolescent rats. Psychoneuroendocrinology, 2007, 319, 636-650.
43. Llorente R, O'Shea, Gutierrez-Lopez MD, Llorente-Berzal A, Colado MI, Viveros MP: Sex-dependent maternal deprivation effects on brain monoamine content in adolescent rats. Neurosci Lett, 2010, 479, 112-117.
44. Lodge DJ, Grace AA: Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res, 2009, 7, 204, 306-312.
45. Lubow RE, Gewirtz JC: Latent inhibition in humans: Data, theory, and implications for schizophrenia. Psychol Bull, 1995, 117, 87-103.
46. Mailman RB, Murthy V: Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des, 2010, 16, 488-501.
47. Markham JA, Taylor AR, Taylor SB, Bell DB, Koenig JI: Characterization of the cognitive impairments induced by prenatal exposure to stress in the rat. Front Behav Neurosci, 2010, 4, 173.
48. Mednick SA, Machon RA, Huttunen MA, Bonett D: Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry, 1988, 45, 189-192.
49. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsycho-pharmacol Biol Psychiatry, 2003, 27, 1159-1172.
50. Meltzer HY, Matsubara S, Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther, 1989, 251, 238-246
51. Morris R: Development of water-maze procedure for studying spatial learning in a rat. J Neurosci Methods, 1984, 11, 47-60.
52. Nagai T, Kitahara Y, Shiraki A, Hikita T, Taya A, Kaibuchi K, Yamada K: Dysfunction of dopamine release in the prefrontal cortex of dysbindin deficient sandy mice: An in vivo microdialisis study. Neurosci Lett, 2010, 470, 134-138.
53. Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T: Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl). 2009, 202, 315-328.
54. Newcomer JW, FaustmanWO,Whiteford HA, Moses JA Jr, Csernansky JG: Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients. Biol Psychiatry, 1991, 29, 855-864.
55. Nowakowska E, Chodera A, Kus K: Influence of olanzapine on cognitive functions and catalepsy in rats after single and chronic administration. Pol J Pharmacol, 1999, 51, 295-300.
56. Nowakowska E, Kus K, Polański A, Burda K, Nowakowska A, Sadowski C: Concomitant use of carbamazepine and olanzapine and the effect on some behavioral functions in rats. Pharmacol Rep, 2011, 63, 372-380.
57. O'Donnell K, O'Connor TG, Glover V: Prenatal stress and neurodevelopment of the child: focus on the HPA Axis and role of the placenta. Dev Neurobiol, 2009, 31, 285-292.
58. Orsetti M, Colella L, Dellarole A, Canonico PL, Ferri S, Ghi P: Effects of chronic administration of olanzapine, amitriptyline, haloperidol or sodium valproate in naive and anhedonic rats. Int J Neuropsychopharmacol, 2006, 8, 427-436.
59. Pawłowski M, Westphal Ł, Wesołowska A: From chlorpomazine to aripiprazol - overview of pharmacotherapy in schizophrenia. Selected antipsychotic drugs - chemistry and biochemical mechanism of action (Polish). Czasopismo Aptekarskie, 2009, 10, 54-65.
60. Pers K, Rajewski A: Associative processes disorders in schizophrenia (Polish). Psychiatr Pol, 2003, 37, 615-626.
61. Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol, 1978, 47, 379-391.
62. Quan MN, Tian YT, Xu KH, Zhang T, Yang Z: Post weaning social isolation influences spatial cognition, prefrontal cortical synaptic plasticity and hippocampal potassium ion channels in Wistar rats. Neuroscience, 2010, 169, 214-222.
63. Reavill C, Kettle A, Holland V, Riley GJ, Blackburn TP: Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol, 1999, 126, 572-574.
64. Renard CE, Dailly E, David DJ, Hascoët M, Bourin M: Neurochemical changes following the mouse forced swimming test but not the tail suspension test. Fundam Clin Pharmacol, 2003, 17, 449-455.
65. Richards JR, Richards IN, Ozery G, Derlet RW: Droperidol analgesia for opioid-tolerant patients. J Emerg Med, 2010, 1-8.
66. Rybakowski J: Neuroprotective effect of antidepressant and mood-stabilizing drugs. Neuropsychiatry Neuropsychol, 2006, 1, 49-55.
67. Rybakowski J: Standards for therapy of bipolar affective disorders (Polish). Wiad Psychiatr, 2004, 4, 279-284.
68. Rzewuska M: Dopaminergic system and antipsychotic drugs (Polish). Psychiatria w Praktyce Klinicznej, 2009, 3, 115-123.
69. Sakaue M, Somboonthum P, Nishihara B, Koyama Y, Hashimoto H, Baba A, Matsuda T: Postsynaptic 5-hydroxytryptamine1A receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol, 2000, 129, 1028-1034.
70. Scherk H, Pajonk FG, Leucht S: Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry, 2007, 64, 442-455.
71. Seckl JR: Glucocorticoid programming of the fetus; adult phenotypes and molecular mechanisms. Mol Cell Endocrinol, 2001, 185, 61-71.
72. Sharp T, Zetterstrom T, Ljungberg T, Ungerstedt U: A direct comparison of amphetamine-induced behaviors and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res, 1987, 401, 322-330.
73. Smith LA, Cornelius V, Warnock A, Bell A, Young AH: Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord, 2007, 9, 394-412.
74. Snigdha S, Neill JC: Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats - a preliminary investigation. Behav Brain Res, 2008, 187, 489-494.
75. Steed E, Jones CA, McCreary AC: Serotonergic involvement in methamphetamine-induced locomotor activity: A detailed pharmacological study. Behav Brain Res, 2011, 220, 9-19.
76. Stefanski R, Goldberg SR: Serotonin 5-HT2 receptor antagonists-potential in the treatment of psychiatric disorders. Drug Ther, 1997, 5, 388-409.
77. Szubert S, Florkowski A, Bobińska K: Impact of stress on plasticity of brain structures and development of chosen psychiatric disorders. Pol Merkur Lekarski, 2008, 24, 140-162.
78. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB et al.: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry, 2003, 60, 1079-1088.
79. Tollefson GD, Sanger TM, Lu Y, Thieme ME: Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psych, 1998, 55, 250-258.
80. van der Zwaal EM, Luijendijk MC, Evers SS, la Fleur SE, Adan RA: Olanzapine affects locomotor activity and meal size in male rats. Pharmacol Biochem Behav, 2010, 97, 130-137.
81. Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, Anderson ER, Snow J, Staib H et al.: Hippocampal volume, memory and cortisol status on major depressive disorder: Effect of treatment. Biol Psychiatry, 2004, 56, 101-112.
82. Wciórka J: Psychopathology (Polish). In: Psychiatry I. Eds. Bilikiewicz A, Pużyński S, Rybakowski J, Wciórka J, Urban & Partner, Wrocław, 2002, 333-335.
83. Weinstock M: Alterations induced by gestational stress in brain morphology and behaviour of the offspring. Prog Neurobiol, 2001, 65, 427-451.
84. Welberg LA, Seckl JR: Prenatal stress, glucocorticoids and the programming of the brain. J Neuroendocrinol, 2001, 13, 113-128.
85. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M et al.: Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol, 2006, 546, 88-94.
86. Woodward ND, Purdon SE, Meltzer HY, Zald DH: A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine and risperidone in schizophrenia. Int J Neuropsychopharmacol, 2005, 8, 457-472.
87. Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I et al.: Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry, 2003, 48, 716-721.
88. Wright P, Meehan K, Birkett M,Wright P, Meehan K, Birkett M: Acomparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther, 2003, 25, 1420-1428.